Related references
Note: Only part of the references are listed.Current status and limitations of immunotherapy for breast cancer
Yoshihisa Tokumaru et al.
SURGERY (2020)
Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
Yoshihisa Tokumaru et al.
CANCER SCIENCE (2020)
High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
Eriko Katsuta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Oncogenic functions of the EMT-related transcription factor ZEB1 in breast cancer
Hua-Tao Wu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
Hideo Takahashi et al.
SCIENTIFIC REPORTS (2020)
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Lu Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Synthetic miR-143 Inhibits Growth of HER2-Positive Gastric Cancer Cells by Suppressing KRAS Networks Including DDX6 RNA Helicase
Yoshihisa Tokumaru et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival
Maiko Okano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis
Maiko Okano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
High expression of bone morphogenetic protein (BMP) 6 and BMP7 are associated with higher immune cell infiltration and better survival in estrogen receptor-positive breast cancer
Eriko Katsuta et al.
ONCOLOGY REPORTS (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor
Takashi Takeshita et al.
SCIENTIFIC REPORTS (2019)
Expression of MicroRNA-9 is Associated With Overall Survival in Breast Cancer Patients
Judith C. Sporn et al.
JOURNAL OF SURGICAL RESEARCH (2019)
Notch1 in Tumor Microvascular Endothelial Cells and Tumoral miR-34a as Prognostic Markers in Locally Advanced Triple-Negative Breast Cancer
Dongmin Kim et al.
JOURNAL OF BREAST CANCER (2019)
Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer
Sumana Narayanan et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu et al.
CELL (2018)
Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Recep Bayraktar et al.
CLINICAL CANCER RESEARCH (2018)
High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy
Tomoaki Terakawa et al.
Oncotarget (2018)
Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer
Tstutomu Kawaguchi et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
MicroRNA-34 family in breast cancer: from research to therapeutic potential
Saber Imani et al.
JOURNAL OF CANCER (2018)
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment
Nathan A. Ungerleider et al.
BREAST CANCER RESEARCH (2018)
Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival
Jessica Young et al.
ONCOTARGET (2017)
MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion
Saber Imani et al.
ONCOTARGET (2017)
Overexpression of suppressive microRNAs, miR-30a and miR-200c are associated with improved survival of breast cancer patients
Tsutomu Kawaguchi et al.
SCIENTIFIC REPORTS (2017)
Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA)
Sara Y. Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer
Brian D. Adams et al.
CANCER RESEARCH (2016)
The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas
Brian D. Adams et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway
Junli Chen et al.
SCIENTIFIC REPORTS (2016)
Quantitative assessment of miR34a as an independent prognostic marker in breast cancer
Seema Agarwal et al.
BRITISH JOURNAL OF CANCER (2015)
Mir-34: A New Weapon Against Cancer?
Gabriella Misso et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer
Xiang H. -F. Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis
Arash Javeri et al.
MEDICAL ONCOLOGY (2013)
The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis
Joy Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer
Hanna Peurala et al.
PLOS ONE (2011)
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis
Nina Raver-Shapira et al.
MOLECULAR CELL (2007)
The monofunctional alkylating agent N-methyl-N '-nitro-N-nitrosoguanidine triggers apoptosis through p53-dependent and -independent pathways
WJ Kim et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)
Share Paper
